What is HC Wainwright’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of FibroGen in a report released on Tuesday, March 18th. HC Wainwright analyst M. Keller expects that the biopharmaceutical company will post earnings of $0.04 per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

Separately, StockNews.com began coverage on FibroGen in a research note on Friday, March 14th. They issued a “hold” rating for the company.

FibroGen Stock Down 6.4 %

FGEN stock opened at $0.32 on Thursday. The firm has a market cap of $31.74 million, a PE ratio of -0.26 and a beta of 0.82. The business has a 50 day moving average of $0.49 and a 200-day moving average of $0.43. FibroGen has a 12-month low of $0.18 and a 12-month high of $2.80.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million during the quarter, compared to the consensus estimate of $24.91 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Sigma Securities LLC bought a new stake in shares of FibroGen in the 4th quarter worth approximately $27,000. Velan Capital Investment Management LP purchased a new stake in FibroGen in the fourth quarter worth $42,000. XTX Topco Ltd raised its stake in shares of FibroGen by 423.8% in the fourth quarter. XTX Topco Ltd now owns 96,025 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 77,693 shares during the period. Franklin Street Advisors Inc. NC lifted its position in shares of FibroGen by 100.0% during the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 100,000 shares during the last quarter. Finally, FMR LLC grew its stake in shares of FibroGen by 21.8% during the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares during the period. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.